Mylan Specialty L.P. Announces 25th Anniversary Celebration of EpiPen® (epinephrine) Auto-Injector
Marketer of EpiPen® Auto-Injector, the No. 1 prescribed epinephrine auto-injector, announces additional efforts to increase anaphylaxis awareness, preparedness and access to treatment for those affected by life-threatening allergies
BASKING RIDGE, N.J., April 25, 2013 /PRNewswire/ -- Mylan Specialty L.P., the fully integrated specialty pharmaceutical business of Mylan Inc. (Nasdaq: MYL), is celebrating the 25th anniversary of the U.S. Food and Drug Administration's (FDA) approval of the EpiPen® (epinephrine) Auto-Injector. This innovative epinephrine auto-injector, the first of its kind, was developed for the emergency treatment of severe allergic reactions (anaphylaxis). Today, with more than 46 million EpiPen Auto-Injectors dispensed, it remains the No. 1 prescribed epinephrine auto-injector. In recognition of this important milestone, Mylan Specialty recently introduced the 25th anniversary "$0 Co-Pay Offer." As is consistent with Mylan's commitment to providing people access to high quality medicine, this co-pay card is available to both cash-paying and commercially insured patients. Certain restrictions apply. Additional information about the co-pay card is available online at EpiPen.com, and the coupon is available to patients through physicians across the country. The "$0 Co-Pay Offer" is valid for up to three EpiPen 2-Pak® cartons or EpiPen Jr 2-Pak® cartons per prescription, as patients may need to access two EpiPen or EpiPen Jr® (epinephrine) Auto-Injectors in multiple locations. Eligible patients can use the offer with an unlimited number of prescriptions until the coupon offer expires on December 31, 2013. "Mylan has a long-standing dedication to increasing access to epinephrine auto-injectors through innovative access solutions such as the EpiPen4Schools program, and we're pleased to continue that commitment by introducing our $0 Co-Pay Offer," said Heather Bresch, CEO of Mylan. Immediate access to epinephrine, the medication delivered by EpiPen Auto-Injector, is a critical component of an anaphylaxis action plan. Since 2009, EpiPen Auto-Injectors have delivered an injection of epinephrine using built-in needle protection, so people never see or are exposed to the needle before and after use. Those known to be at risk for anaphylaxis should have an action plan that includes avoiding known allergens, recognizing symptoms, having access to two epinephrine auto-injectors at all times and seeking immediate emergency medical care should anaphylaxis occur. "As part of this important anniversary year we also want to celebrate the millions of people, from emergency responders and school nurses to caregivers and patients, who are trained on and prepared with our EpiPen Auto-Injector in the event anaphylaxis occurs," said Bresch. "We recognize that with the increase in food allergies, that the risk of anaphylaxis may be on the rise, and as the leading marketers of epinephrine auto-injectors for 25 years, we will continue to introduce educational efforts that lead to greater anaphylaxis awareness and preparedness." As Mylan Specialty rolls out several new programs this year, the company will continue to partner with trusted advocacy organizations from across the country to increase awareness and preparedness of life-threatening allergic reactions. Advocacy organizations including Allergy & Asthma Network Mothers of Asthmatics (AANMA), the American Latex Allergy Association (ALAA), Asthma and Allergy Foundation of America (AAFA), Food Allergy Research & Education (FARE), Kids With Food Allergies Foundation (KFA) and the National Association of School Nurses (NASN) continue with outstanding success to unite their members around this important issue. Mylan Specialty is proud to collaborate with these allies on both new and existing educational activities focusing on anaphylaxis awareness and preparedness. "For 25 years, the EpiPen Auto-Injector has helped people with potentially life-threatening allergies be better prepared for an anaphylactic reaction, whether they are going out to dinner, heading off for the first day of school or traveling to a foreign destination," said Bill McLin, President and CEO of AAFA. "AAFA is proud to partner with Mylan Specialty and to continue our work with them on many initiatives to increase awareness about life-threatening allergies and improve access to emergency epinephrine treatment." Additional plans by Mylan Specialty to honor the 25th anniversary of EpiPen Auto-Injector will be announced soon. For more information on anaphylaxis, life-threatening allergies and EpiPen Auto-Injector, visit epipen.mediaroom.com. Indications Important Safety Information Tell your doctor if you have certain medical conditions such as asthma, depression, thyroid disease, Parkinson's disease, diabetes, high blood pressure and heart disease, have any other medical conditions, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. Be sure to also tell your doctor all the medicines you take, especially medicines for asthma. If you have certain medical conditions, or take certain medicines, your condition may get worse or you may have longer lasting side effects when you take the EpiPen or EpiPen Jr Auto Injector. The most common side effects may include increase in heart rate, stronger or irregular heartbeat, sweating, nausea and vomiting, difficulty breathing, paleness, dizziness, weakness or shakiness, headache, apprehension, nervousness or anxiety. These side effects usually go away quickly, especially if you rest. Talk to your healthcare professional to see if EpiPen or EpiPen Jr Auto-Injector is right for you. Please click here or visit www.EpiPen.com for the EpiPen Auto-Injector prescribing information. You are encouraged to report negative side effects of prescription drugs to the FDA. About the "$0 Co-Pay Offer" Card About the EpiPen4Schools Program About Anaphylaxis About EpiPen® Auto-Injector About Mylan Specialty About Mylan EpiPen®, EpiPen Jr®, EpiPen 2-Pak®, and EpiPen Jr 2-Pak® are registered trademarks of Mylan Inc. licensed exclusively to its wholly-owned subsidiary, Mylan Specialty L.P. EpiPen4Schools is a trademark of Mylan Specialty L.P. © 2013 Mylan Specialty L.P. All rights reserved. EPI13-8026/EPI547903-01 SOURCE Mylan Specialty L.P. |
|